Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease.

ARC-HD results showed that treatment with AUSTEDO had a safety and tolerability profile comparable with the First-HD randomized, double-blind, placebo-controlled, 12-week study. In ARC-HD medication compliance rates were greater than 90% over the ~3 year open-label extension period. Over this full period, AUSTEDO improved and maintained chorea control in both the Rollover cohort and the Switch cohort, as measured by the Unified Huntington’s Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score.1

“These data provide important insight into the long-term use of deutetrabenazine for the treatment of chorea associated with Huntington’s disease, which can have a significant functional impact on people’s lives,” said Samuel Frank, MD, Associate Professor of Neurology and Director of HDSA Center of Excellence at Beth Israel Deaconess Medical Center, Boston, and lead author of the study. “Results of this study add to the safety and tolerability profile and support deutetrabenazine as a treatment choice for this progressive condition. We are deeply grateful to the researchers, patients and their families who played an integral role in this study.”

Read the Complete Article